{"entity":{"id":"ltz-232","kind":"drug","name":"LTZ-232","aka":[],"tldr":"LTZ-232 is an experimental bispecific antibody from LTZ Therapeutics, in phase 1 trials for metastatic colorectal cancer, other advanced solid tumours and malignant ascites.","summary":"LTZ-232 is a bispecific antibody (myeloid cell engager) from LTZ Therapeutics. A first-in-class bispecific myeloid engager targeting EpCAM, built on the company's Universal Myeloid Cell Engager (U-MCE) platform. Its furthest stage is phase 1, for metastatic colorectal cancer, other advanced solid tumours and malignant ascites. ClinicalTrials.gov registers it in one study linked below. FDA IND cleared July 2026; first participant dosed in phase 1/1b, announced 29 October 2026 (NCT07878988). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"LTZ Therapeutics: ltztherapeutics.com","url":"https://www.ltztherapeutics.com/html/news/146.html"},{"label":"LTZ Therapeutics: ltztherapeutics.com","url":"https://www.ltztherapeutics.com/html/news/146.html"},{"label":"LTZ Therapeutics: ltztherapeutics.com","url":"https://www.ltztherapeutics.com/pipeline/index.html"},{"label":"ClinicalTrials.gov: trials of LTZ-232","url":"https://clinicaltrials.gov/search?intr=LTZ-232"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal","metastatic-cancer"],"sections":[],"technologies":[],"targets":["epcam"],"drugs":[],"companies":["ltz-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07878988"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"LTZ-232","modality":"Bispecific antibody (myeloid cell engager)","mechanism":"A first-in-class bispecific myeloid engager targeting EpCAM, built on the company's Universal Myeloid Cell Engager (U-MCE) platform.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ltz-232/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/"}],"company":[{"id":"ltz-therapeutics","kind":"company","name":"LTZ Therapeutics","route":"/companies/ltz-therapeutics/"}],"trial":[{"id":"nct07878988","kind":"trial","name":"This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors","route":"/trials/nct07878988/"}]}}